Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
10.5 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
21 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
42mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
55 mg Montelukast1件: Montelukast1件: D08229 1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
6AK002----1件: 98
7Allergy immunotherapy (allergy shots)----1件: 98
8Alpha-proteinase inhibitor----1件: 98
9AMG 1571件: Tezepelumab1件: D11771 1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98
10AMG157----1件: 98
11APD334----5件: 93, 96, 97, 98, 269
12APT-1011----1件: 98
13APT-1011 - 3 mg----1件: 98
14APT-1011 3 mg HS----1件: 98
15AQ280----1件: 98
16AR401959 L-arginine1件: Arginine1件: D02982 --3件: 96, 97, 98
17Arginine1件: Arginine1件: D02982 --11件: 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299
18Baked Milk1件: Cow milk---1件: 98
19Barzolvolimab----1件: 98
20Beclomethasone dipropionate1件: Beclomethasone dipropionate1件: D00689 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98
21Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
22Bethanechol1件: Bethanechol---1件: 98
23BT----3件: 96, 97, 98
24BT-11 1000mg----3件: 96, 97, 98
25BT-11 500mg----1件: 98
26BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
27Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
28Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
29Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
30Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31Budesonide 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
32Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
33Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
34Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
35Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
36Budesonide Gel1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
37Budesonide oral suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
38Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
39Budesonide Orodispersible Tablets (Jorveza)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
40Budesonide plus Prevacid1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
41BUET 0.5 mg----1件: 98
42BUET 1 mg----1件: 98
43BUET 1mg----1件: 98
44BUET 2mg----1件: 98
45BUL 0.5 mg----1件: 98
46BUL 1 mg----1件: 98
47BUU 0.4mg/ml----1件: 98
48CALY-002----1件: 98
49CC----13件: 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271
50CC-93538----1件: 98
51Cendakimab----1件: 98
52Citalopram1件: Citalopram1件: D07704 1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬7件: 6, 8, 13, 18, 46, 98, 127
53Compressa effervescente 0,5 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
54Compressa effervescente 1 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
55Cromolyn1件: Cromoglicic acid1件: D07753 --3件: 2, 85, 98
56CYP substrates----1件: 98
57Dexlansoprazole1件: Dexlansoprazole1件: D08903 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
58Dupilumab1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬5件: 51, 97, 98, 160, 162
59Dupilumab (blinded)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
60Dupilumab (open-label)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
61Dupixent1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162
62Else nutrition formula----1件: 98
63Eosinophilic Esophagitis (E0E) food introduction-2nd----1件: 98
64Eosinophilic Esophagitis (EoE) food introduction-1st----1件: 98
65Eosinophilic Esophagitis (EoE) Food introduction-3rd dose----1件: 98
66EP-104IAR----1件: 98
67ESO-101----1件: 98
68Esomeprazole1件: Esomeprazole1件: D07917 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬8件: 13, 46, 86, 98, 107, 113, 298, 299
69Etrasimod1件: Etrasimod1件: D10930 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98
70Etrasimod L-arginine2件: Arginine,
Etrasimod		2件: D02982 ,
D10930 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98
71EUR-1100----1件: 98
72Famotidine1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬5件: 6, 46, 86, 98, 107
73Fasenra1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
74Florence 30 µg/mL----1件: 98
75Florence 60 µg/mL----1件: 98
76Florence 90 µg/mL----1件: 98
77Flovent----1件: 98
78Fluticasone1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 299
79Fluticasone MDI1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
80FLUTICASONE PROPIONATE2件: Fluticasone,
Fluticasone propionate		2件: D01708 ,
D07981 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 228
81Fluticasone Propionate, USP1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
82Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318
83High dose budesonide suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
84High dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
85Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
86Inhaled/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
87Intubated with Propofol (IP)1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98
88Intubated with Sevoflurane (IS)1件: Sevoflurane1件: D00547 --1件: 98
89IRL201104----1件: 98
90Jorveza1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
91Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
92Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
93Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
94Jorveza 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
95L-arginine1件: Arginine1件: D02982 --8件: 46, 67, 78, 96, 97, 98, 113, 299
96Lansoprazole1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬7件: 63, 71, 85, 98, 166, 222, 299
97Lirentelimab1件: Lirentelimab1件: D11906 1件: SIGLEC8 💬-1件: 98
98Lirentelimab (AK002)1件: Lirentelimab1件: D11906 1件: SIGLEC8 💬-1件: 98
99Loratadine1件: Loratadine1件: D00364 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬4件: 13, 46, 89, 98
100Losartan1件: Losartan1件: D08146 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
101LOSARTAN POTASSIUM2件: Losartan,
Potassium		2件: D08146 ,
D08403 		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215
102Low dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
103MEDI-563----5件: 44, 45, 98, 162, 299
104MEDI99291件: Tezepelumab1件: D11771 1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98
105MEDI9929 anti-TSLP mAb (AMG157)1件: Tezepelumab1件: D11771 1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98
106MEPOLIZUMAB1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162
107Mepolizumab 100 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
108Mepolizumab 300 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
109Mesalamine1件: Mesalazine1件: D00377 --4件: 96, 97, 98, 164
110Mesalamine Oral Product1件: Mesalazine1件: D00377 --1件: 98
111Milk1件: Cow milk---1件: 98
112Mometasone1件: Mometasone1件: D08227 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
113MOMETASONE FUROATE2件: Mometasone,
Mometasone furoate		2件: D00690 ,
D08227 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
114Montelukast1件: Montelukast1件: D08229 1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬8件: 6, 13, 46, 61, 63, 85, 98, 228
115Montelukast/ Singulair1件: Montelukast1件: D08229 1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
116Nasonex----1件: 98
117OC000459----1件: 98
118OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
119Oral Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
120Oral Budesonide Suspension (MB-9)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
121Oral Budesonide Suspension (OBS)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
122Oral cromolyn sodium1件: Cromoglicic acid1件: D07753 --1件: 98
123Oral Viscous Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
124Oral Viscous Budesonide (OVB)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
125Picoprep----1件: 98
126Potassium1件: Potassium1件: D08403 --13件: 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235
127PROPOFOL1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬8件: 6, 21, 22, 34, 46, 70, 98, 296
128QAX576----4件: 51, 85, 96, 98
129Reslizumab1件: Reslizumab1件: D08985 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬2件: 44, 98
130RPC4046----1件: 98
131SB-240563----3件: 44, 45, 98
132SCH55700----1件: 98
133Sevoflurane1件: Sevoflurane1件: D00547 --7件: 6, 21, 22, 34, 98, 225, 296
134Sirolimus1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬35件: 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331
135Steroid and Proton Pump Inhibitor Therapy----1件: 98
136Sucralfate1件: Sucralfate1件: D00446 --1件: 98
137Swallowed fluticasone1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
138Tezepelumab1件: Tezepelumab1件: D11771 1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98
139Tezepelumab via APFS1件: Tezepelumab1件: D11771 1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98
140Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
141Viaskin Milk 500 mcg1件: Cow milk---1件: 98
142Viscous/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
143Vonoprazan1件: Vonoprazan1件: D11784 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 63, 98
144Zofran - no intubation----1件: 98